webinar register page

Webinar banner
Early Cancer Recurrence Detection: A Tumor-Informed Approach
Molecular residual disease (MRD) detection is emerging as a powerful and non-invasive tool for improving the management of cancer in the post-operative treatment setting. Using circulating tumor DNA can help accurately identify MRD sooner than current standard of care tools but choosing the right assay with proven performance and high sensitivity is key.

Join us for this live Clinical OMICs webinar for a dynamic discussion with our esteemed guests Dr. Gregory Botta from UC San Diego and Dr. Angel Rodriguez from Natera, who will review the value of a tumor informed approach to optimize patient management in the adjuvant treatment setting.

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.


Gregory Botta, MD, PhD
Medical Oncologist
UC San Diego

Angel Rodriguez, MD
Medical Director, Oncology

Apr 22, 2021 05:00 PM in Eastern Time (US and Canada)

* Required information

By registering, I agree to the Privacy Statement and Terms of Service.



Gregory Botta, MD, PhD
Medical Oncologist @UC San Diego
Dr. Gregory Botta is a physician-scientist and medical oncologist specializing in gastrointestinal tumors at the University of California San Diego Moores Cancer Center. He has a research laboratory within the Cancer Center to expand translational cancer treatment trials for oncology patients. He completed a B.S. in Information Systems and Biomedical Engineering at Carnegie Mellon University and received his M.D. and Ph.D between Drexel University and the University of Pennsylvania in Molecular Biology and Genetics. His clinical training was completed at Scripps MD Anderson Cancer Center.
Angel Rodriguez, MD
Medical Director, Oncology @Natera
Dr. Angel Augusto Rodriguez is a board-certified medical oncologist who specializes in breast medical oncology and conducted clinical research with circulating tumor DNA. Before joining Natera, Dr. Rodriguez practiced at Austin Cancer Centers and Houston Methodist Cancer Center where he was Director of the Clinical Trials Office and the Triple Negative Breast Cancer Clinic. While at Houston Methodist he was principal investigator of clinical trials and conducted clinical research with circulating tumor DNA.